查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1609599

抗凝血中和劑市場規模、佔有率、趨勢分析報告：按產品類型、分銷管道、地區和細分市場預測，2025-2030 年

Anticoagulant Reversal Drugs Market Size, Share & Trends Analysis Report By Product Type (Andexanet Alfa, Idarucizumab, Phytonadione (Vitamin K)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

抗凝血中和劑市場成長與趨勢：

Grand View Research 的最新報告顯示，到 2030 年，全球抗凝血逆轉市場規模預計將達到 27.8 億美元。

預計2025年至2030年複合年成長率為12.3%。出血性疾病的增加、新藥的推出以及需要抗凝血治療的病例數量的增加是預計在預測期內推動市場成長的一些因素。

2015年10月，勃林格殷格翰製藥公司的Praxbind（idarucizumab）核准作為一種抗凝血逆轉劑，適用於在緊急手術期間接受Pradaxa（Dabigatran）治療且出現失控或危及生命的出血的患者。因此，這種抗凝血逆轉的可用性將使醫生和患者更有信心地考慮這種治療方法，從而增加對抗凝血逆轉的需求。

血友病等出血性疾病可以是後天性或遺傳性的。然而，其他出血性疾病也可能由愛滋病毒、貧血、白血病、肝硬化和維生素 K 缺乏等疾病引起。根據國家心肺血液研究所的數據，美國有超過 300 萬人患有貧血，使其成為最常見的血液疾病。白血病和淋巴瘤協會 (LLS) 表示，預計 2020 年被診斷出患有白血病的人數約為 60,530 人。出血性疾病的增加增加了抗凝血劑的需求並刺激了市場成長。

然而，這些抗凝血療法的高成本預計將抑制市場成長。根據美國心臟學會的資料，4-F PCC (Kcentra) 可用於治療由利伐沙班和Apixaban引起的出血病例，給藥劑量為 50 單位/公斤。其平均批發價為每單位 2.90 美元，因此治療體重 100 公斤的患者大約需要 14,500 美元。

抗凝血中和劑市場報告亮點：

  • idarucizumab 細分市場在 2024 年以 36.8% 的銷售佔有率佔據主導地位。
  • 醫院藥局2024年銷售佔有率最大，為48.6%，佔市場主導地位。
  • 北美抗凝血逆轉劑市場主導全球市場，2024年銷售佔有率為38.6%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章抗凝血中和劑市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章抗凝血中和劑市場：依產品類型進行的商業分析

  • 產品類型市場佔有率，2024 年和 2030 年
  • 產品類型細分儀表板
  • 2018-2030 年按產品類型分類的市場規模、預測與趨勢分析
  • 凝血酶原複合物濃縮物
  • 植物萘二酮（維生素 K）
  • 安德薩內特阿爾法
  • 伊達賽珠單抗
  • 魚精蛋白
  • 其他

第5章抗凝血中和劑市場：按分銷管道進行的業務分析

  • 2024 年及 2030 年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 2018-2030 年按分銷管道分類的市場規模、預測與趨勢分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第6章抗凝血中和劑市場：區域估計/趨勢分析與產品類型趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 按國家/地區分類，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類，2018-2030
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 按國家/地區分類，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章抗凝血中和劑市場：按分銷管道分類的區域估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 按國家/地區分類，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類，2018-2030
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 按國家/地區分類，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/名單
    • Pfizer Inc
    • AstraZeneca
    • Dr. Reddy's Laboratories Ltd
    • Endo International plc
    • Teva Pharmaceutical Industries Ltd
    • Sun Pharmaceutical Industries Ltd
    • Mylan NV
    • Novartis AG.
    • Lupin
    • Cipla Inc
Product Code: GVR-4-68039-293-5

Anticoagulant Reversal Drugs Market Growth & Trends:

The global anticoagulant reversal drugs market size is expected to reach USD 2.78 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 12.3% from 2025 to 2030. The rising number of bleeding disorders, the introduction of new drugs, and the growing number of cases requiring anticoagulant therapies are some of the factors anticipated to foster market growth during the forecast period.

In October 2015, Praxbind (idarucizumab) by Boehringer Ingelheim Pharmaceuticals was approved as an anticoagulant reversal drug indicated for patients treated with Pradaxa (dabigatran) during emergency surgery or uncontrolled or life-threatening bleeding. Hence, the availability of these anticoagulation reversal drugs allows doctors and patients to consider such treatment options with greater confidence, therefore boosting the demand for anticoagulant reversal drugs.

Bleeding disorders like hemophilia can be acquired or inherited. However, other bleeding disorders can occur from conditions, such as HIV, anemia, leukemia, cirrhosis of the liver, and vitamin K deficiency. According to the National Heart, Lung, and Blood Institute, more than 3 million people in the U.S. are affected with anemia, which is the most common blood disorder. The Leukemia & Lymphoma Society (LLS) stated that in the year 2020, the number of people expected to be diagnosed with leukemia is around 60,530. A rise in bleeding disorders is increasing the demand for anticoagulants, thus fueling the market growth.

However, the high cost of these reversal therapies is anticipated to restrain the market growth. As per the American College of Cardiology, 4-F PCC (Kcentra) helps in treating bleeding cases caused by rivaroxaban and apixaban and it is dosed at 50 units/kg. Its average wholesale price is USD 2.90 per unit, therefore treating a patient whose weight is 100 kg would cost around USD 14,500.

Anticoagulant Reversal Drugs Market Report Highlights:

  • The idarucizumab segment dominated the market, with a revenue share of 36.8% in 2024, driven by its high specificity for dabigatran as an effective option for reversing anticoagulation in emergencies.
  • Hospital pharmacies dominated the market with the largest revenue share of 48.6% in 2024, driven by the need for immediate access to anticoagulant reversal agents in emergencies.
  • North America anticoagulant reversal drugs market dominated the global market with a revenue share of 38.6% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Anticoagulant Reversal Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Anticoagulant Reversal Drugs Market: Product Type Business Analysis

  • 4.1. Product Type Market Share, 2024 & 2030
  • 4.2. Product Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product Type, 2018 to 2030 (USD Million)
  • 4.4. Prothrombin Complex Concentrates
    • 4.4.1. Prothrombin Complex Concentrates Market, 2018 - 2030 (USD Million)
  • 4.5. Phytonadione (Vitamin K)
    • 4.5.1. Phytonadione (Vitamin K) Market, 2018 - 2030 (USD Million)
  • 4.6. Andexanet Alfa
    • 4.6.1. Andexanet Alfa Market, 2018 - 2030 (USD Million)
  • 4.7. Idarucizumab
    • 4.7.1. Idarucizumab Market, 2018 - 2030 (USD Million)
  • 4.8. Protamine
    • 4.8.1. Protamine Market, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Anticoagulant Reversal Drugs Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacy
    • 5.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 5.5. Retail Pharmacy
    • 5.5.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 5.6. Online Pharmacy
    • 5.6.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 6. Anticoagulant Reversal Drugs Market: Regional Estimates & Trend Analysis by Product Type

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Anticoagulant Reversal Drugs Market: Regional Estimates & Trend Analysis by Distribution Channel

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Anticoagulant Reversal Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Anticoagulant Reversal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Pfizer Inc
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. AstraZeneca
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Dr. Reddy's Laboratories Ltd
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Endo International plc
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Teva Pharmaceutical Industries Ltd
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Sun Pharmaceutical Industries Ltd
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Mylan N.V.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Novartis AG.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Lupin
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Cipla Inc
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global anticoagulant reversal drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 5. Global anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6. North America anticoagulant reversal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 7. North America anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 8. North America anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9. U.S. anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 10. U.S. anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11. Canada anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 12. Canada anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13. Mexico anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 14. Mexico anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15. Europe anticoagulant reversal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 16. Europe anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 17. Europe anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 18. UK anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 19. UK anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Germany anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 21. Germany anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22. France anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 23. France anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. Italy anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 25. Italy anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26. Spain anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 27. Spain anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28. Norway anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 29. Norway anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. Denmark anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 31. Denmark anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32. Sweden anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 33. Sweden anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific anticoagulant reversal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 36. Asia Pacific anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37. Japan anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 38. Japan anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39. China anticoagulant reversal drugs market, by product type, 2018-2030 (USD Million)
  • Table 40. China anticoagulant reversal drugs market, by distribution channel, 2018-2030 (USD Million)
  • Table 41. India anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 42. India anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43. Australia anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 44. Australia anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. South Korea anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 46. South Korea anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47. Thailand anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 48. Thailand anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49. Latin America anticoagulant reversal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 50. Latin America anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 51. Latin America anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Billion
  • Table 52. Brazil anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 53. Brazil anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54. Argentina anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 55. Argentina anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa anticoagulant reversal drugs market, by country, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 58. Middle East & Africa anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59. South Africa anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 60. South Africa anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 62. Saudi Arabia anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 63. UAE anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 64. UAE anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65. Kuwait anticoagulant reversal drugs market, by product type, 2018 - 2030 (USD Million)
  • Table 66. Kuwait anticoagulant reversal drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Anticoagulant reversal drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product type outlook (USD Billion)
  • Fig. 10 Distribution channel outlook (USD Billion)
  • Fig. 11 Competitive landscape
  • Fig. 12 Anticoagulant reversal drugs market dynamics
  • Fig. 13 Anticoagulant reversal drugs market: Porter's five forces analysis
  • Fig. 14 Anticoagulant reversal drugs market: PESTLE analysis
  • Fig. 15 Anticoagulant reversal drugs market: Product type segment dashboard
  • Fig. 16 Anticoagulant reversal drugs market: Product type market share analysis, 2024 & 2030
  • Fig. 17 Prothrombin complex concentrates market, 2018 - 2030 (USD Million)
  • Fig. 18 Phytonadione (Vitamin K) market, 2018 - 2030 (USD Million)
  • Fig. 19 Andexanet alfa market, 2018 - 2030 (USD Million)
  • Fig. 20 Idarucizumab market, 2018 - 2030 (USD Million)
  • Fig. 21 Protamine market, 2018 - 2030 (USD Million)
  • Fig. 22 Others market, 2018 - 2030 (USD Million)
  • Fig. 23 Anticoagulant reversal drugs market: Distribution channel segment dashboard
  • Fig. 24 Anticoagulant reversal drugs market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 25 Hospital pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 26 Retail pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 27 Online pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 28 Anticoagulant reversal drugs market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 48 Norway country dynamics
  • Fig. 49 Norway anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 57 China country dynamics
  • Fig. 58 China anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 59 India country dynamics
  • Fig. 60 India anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 67 Latin America anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 68 Brazil country dynamics
  • Fig. 69 Brazil anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 70 Argentina country dynamics
  • Fig. 71 Argentina anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 72 MEA anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 73 South Africa country dynamics
  • Fig. 74 South Africa anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 75 Saudi Arabia country dynamics
  • Fig. 76 Saudi Arabia anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 77 UAE country dynamics
  • Fig. 78 UAE anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 79 Kuwait country dynamics
  • Fig. 80 Kuwait anticoagulant reversal drugs market, 2018 - 2030 (USD Million)
  • Fig. 81 Company categorization
  • Fig. 82 Company market position analysis
  • Fig. 83 Strategic framework